Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone scan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,307 result(s) found for: Bone scan. Displaying page 2 of 66.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-000511-25 Sponsor Protocol Number: 20040114 Start Date*: 2004-10-08
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates
    Medical condition: Bone metastases of solid tumors (except lung) or multiple myeloma bone disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003470-26 Sponsor Protocol Number: 07TASQ08 Start Date*: 2007-10-17
    Sponsor Name:Active Biotech Research AB
    Full Title: Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer. Final Protocol dated 2...
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000981-46 Sponsor Protocol Number: IC2015-13 Start Date*: Information not available in EudraCT
    Sponsor Name:INSTITUT CURIE
    Full Title: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years -
    Medical condition: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055101 Bone cancer metastatic PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002995-13 Sponsor Protocol Number: S28720 UZ KUL Start Date*: 2006-01-23
    Sponsor Name:UZLeuven
    Full Title: An open label Phase II trial to investigate the cardiac effects of pegylated liposomal doxorubicine (Caelyx) in elderly breast cancer patients with new imaging and biochemical techniques.
    Medical condition: histologically proven early breast cancer requiring adjuvant chemotherapy according to the treating physician (lymph node positive or other features of high risk according to St-Gallen criteria). 1...
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002957-46 Sponsor Protocol Number: 56021927PCR3015 Start Date*: 2020-05-13
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with Hormone-Sensitive Pr...
    Medical condition: High risk recurrent prostate cancer previously treated with radical prostatectomy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004091-34 Sponsor Protocol Number: CCR3972 Start Date*: 2014-03-26
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Institute of Cancer Reseacrh
    Full Title: A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer
    Medical condition: Metastatic Castration- Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-000305-21 Sponsor Protocol Number: ASCB-Onco-2336-2017 Start Date*: 2017-10-20
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Assessment of bone response after LHRH-A and Enzalutamide plus minus Zoledronic Acid in prostate cancer patients with hormone sensitive metastatic bone disease: a prospectic, phase II, randomized, ...
    Medical condition: prostate cancer with hormone sensitive metastatic bone disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10036927 Prostate neoplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002832-24 Sponsor Protocol Number: CZOL446GDE21 Start Date*: 2005-07-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine...
    Medical condition: Hormonreceptor positive breast cancer in premenopausal women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002415-10 Sponsor Protocol Number: PROCoMBO Start Date*: 2014-02-11
    Sponsor Name:University Medical Center Groningen
    Full Title: [18F]-labelled FDHT in PET/CT for detection and staging of bone metastases in hormone naïve prostate cancer
    Medical condition: Hormone naive prostate cancer, metastasized to bone (2 or more bone metastases).
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001376-12 Sponsor Protocol Number: BISMARK 2005 Start Date*: 2005-08-19
    Sponsor Name:University of Sheffield
    Full Title: Cost-effective use of BISphonphonates in metastatic bone disease - a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule.
    Medical condition: Advanced breast cancer with bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005667-34 Sponsor Protocol Number: G0701625 Start Date*: 2009-01-16
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Randomised Trial of Genetic Testing and Targeted Zoledronic acid therapy to Prevent SQSTM1 Mediated Paget's Disease (Zoledronate in the Prevention of Paget's).
    Medical condition: Paget's disease of the bone (PDB)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10033363 Paget's disease of bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed) IE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-004850-40 Sponsor Protocol Number: 01-0712-2017 Start Date*: 2018-04-25
    Sponsor Name:VU Medical Center, department of Rheumatology
    Full Title: [18F]Fluoride PET-CT imaging for detection and monitoring of bone formation in spondyloarthritis
    Medical condition: Spondyloarthritis (ankylosing spondylitis and psoriatic arthritis)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000075-16 Sponsor Protocol Number: BAY88-8223/16216 Start Date*: 2012-06-20
    Sponsor Name:Bayer HealthCare AG
    Full Title: Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis
    Medical condition: Castrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer patients with bone metastasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10036916 Prostate cancer stage D LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) NO (Completed) FI (Completed) BE (Completed) ES (Completed) CZ (Completed) IE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021870-12 Sponsor Protocol Number: 10TASQ10 Start Date*: 2011-02-15
    Sponsor Name:Active Biotech AB
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer
    Medical condition: Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed) BE (Completed) DE (Completed) LV (Completed) NL (Completed) CZ (Completed) ES (Completed) LT (Completed) IT (Completed) SK (Completed) GR (Completed) EE (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-005088-17 Sponsor Protocol Number: CZOL446EHU03 Start Date*: 2005-05-26
    Sponsor Name:Novartis Hungária Ltd.
    Full Title: A multicenter, Open-label Study to Determine the Effect of I.V. Zometa on Pain and Quality of Life in Patients with Bone Metastases with or without Skeletal Related Events (SREs) Resulting from Bre...
    Medical condition: Patients will have bone metastases with or without skeletal related events (SREs) from breast cancer and prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-000592-24 Sponsor Protocol Number: PTH2008002 Start Date*: 2008-08-11
    Sponsor Name:Berufsgenossenschaftliche Unfallklinik
    Full Title: A Randomized Open Clinical Study of Daily Subcutaneous Parathyroid Hormone (1-34) / Teriparatide Injection on the Consolidation of Regenerated Bone Formed after Distraction Osteogenesis.
    Medical condition: Patients with tibial bone defects due to resection after osteomyelitis who are undergoing bone segment transport
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046080 Unspecified osteomyelitis involving lower leg LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001222-26 Sponsor Protocol Number: 2013-1 Start Date*: 2013-08-08
    Sponsor Name:Aalborg University Hospital
    Full Title: Markers of bonestatus in Diabetes Mellitus patients (type 1 and type 2) and the effect of antiresorptive treatment on glycemic markers.
    Medical condition: Diabetes Mellitus and Osteopenia/Osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-006195-11 Sponsor Protocol Number: BC1-06 Start Date*: 2008-03-26
    Sponsor Name:Algeta ASA
    Full Title: A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.
    Medical condition: Hormone refractory prostate cancer with skeletal metastases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027452 Metastases to bone PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) BE (Completed) SK (Completed) ES (Completed) CZ (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003811-23 Sponsor Protocol Number: ABIDO Start Date*: 2013-12-26
    Sponsor Name:SOGUG - Spanish Oncology Genitourinary Group
    Full Title: Abirateriona acetate maintenance in combination with docetaxel after disease progression to abiraterona acetate in metastatic castration resistant prostate cancer. Randomized phase II study.
    Medical condition: Metastatic castration resistant prostate cáncer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004778-99 Sponsor Protocol Number: 120895 Start Date*: 2005-06-14
    Sponsor Name:Pediatric Unit, Hillerød Hospital
    Full Title: The growth of the internal genitalia and the bone mineralization during hormonal replacement therapy and the presence of aortic root dilatation in girls with Turner Syndrome
    Medical condition: Turner Syndrome is a common chromosomal abnormalities, characterized by one X-chromosome or a partial deletion in all or some cell-lines. The syndrome is known for features as short stature and abs...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 18:52:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA